PerpEquities

Equity · Healthcare

Pfizer Inc. (PFE) perpetual futures

PFE perpetual futures on 4 crypto exchanges – live perp price vs the stock, funding rate, open interest and where to trade PFEUSDT.

Pfizer Inc. is a global biopharmaceutical company that researches, develops, manufactures, and markets medicines and vaccines for diverse therapeutic areas, including COVID-19 treatments like Paxlovid and vaccines like Comirnaty.

$27.80-1.1%NYSE closed
Open in terminal

Price chart

 

Use the left and right arrow keys to inspect points on the chart.

Collecting venue price data...
venue perp mark · Ourbit (PFE/USDT)
Auto: highest-volume live perp venueOpen in TradingView

Trading data

Perpetual market activity

4/5 live markets
Venues
5
Live markets
4/5
24h volume
$118.1KCoverage: 3/4 marketsExchange-reported volume: $3.2M
Open interest
$210.4KCoverage: 3/4 markets
Best liquidity
$10.3K
Ourbit
Tightest spread
+28.8 bps
Ourbit
Highest volume
$89.8K
MEXC
Settlement mix
USDT · 4/5
Perp/spot vol.
0.00x
Spot volume $970.6M
OI / float
0.00%
Float $158.2B
Spot performance
1D-1.14%
5D-2.87%
1M-2.28%
6M-0.11%
YTD+11.65%
1Y+5.18%

Venue matrix

5 markets

Some venue links are sponsored. We may receive a commission, and eligible users may occasionally receive trading-fee discounts, at no additional cost to you.

Trade
MEXCTradePFE/USDTTrading$27.79-14.5% APR
-0.013% every 8h
+28.8 bps$4.2K$89.8K$73.6KUSDT20x
Helix (Injective)TradePFE/USDCTrading$27.80+24.1% APR
+0.00275% every 1h
--$28.2K-USDC12x
Gate.ioTradePFE/USDTTrading$27.810.0% APR
0.000% every 8h
+81.3 bps-$158$21.9KUSDT20x
BingXTradePFE-USDTWatchlist------USDT-
OurbitTradePFE/USDTTrading$27.80-14.5% APR
-0.013% every 8h
+28.8 bps$10.3K$3.1M⚠$114.9KUSDT20x

Unverified volume: implausibly high against open interest, a typical sign of wash trading. These venues are listed last.

Tradability

Execution quality

Entry cost and depth per venue at $1k–$100k

No sufficient depth · 0 of 4 venues absorb $10k

Too thin: Ourbit, MEXC

No fresh book data: Helix (Injective), Gate.io

Taker execution estimate incl. approx. fees - maker fills are not guaranteed.

Best venues for this underlying

Best liquidity

PFE

Tightest spread

PFE

Highest volume

PFE

Funding history

Stored venue snapshots by market

Company data

Company fundamentals

Updated 2h ago
Market cap
$158.4B
Updated 2h ago
Revenue
$63.7B
Trailing 12 months
Revenue growth
-1%
Next fiscal year
Profit margin
+6.8%
P/E
36.7
Peer P/E 25.1
Free cash flow
$11B
Trailing 12 months
More metrics
Net income
$4.3B
Trailing 12 months
P/S
2.5
Peer P/E
25.1
Similar listed perps
Revenue estimate
$62.2B
Next fiscal year
Earnings
2026-11-03
Revenue est. $15.9B · Updated 2h ago
Dividend
$0.43
2026-07-24

Fundamental detail

Annual + quarterly
Latest revenue$62.6B
Net margin+12.4%
Free cash flow$9.1B
Net debt$66.3B
2020$41.7B
2021$81.3B
2022$100.3B
2023$59.6B
2024$63.6B
2025$62.6B
PeriodRevenueGrowthNet incomeFCF
2020$41.7B+1%$9.2B$11.6B
2021$81.3B+95%$22.1B$29.9B
2022$100.3B+23%$31.4B$26B
2023$59.6B-41%$2.1B$4.8B
2024$63.6B+7%$8B$9.8B
2025$62.6B-2%$7.8B$9.1B
PeriodGross marginOperating marginNet marginROEROA
2020+71.7%+21.8%+22.0%+14.5%+5.9%
2021+57.7%+25.6%+27.2%+28.7%+12.2%
2022+61.9%+37.4%+31.3%+32.8%+15.9%
2023+50.9%+8.9%+3.6%+2.4%+0.9%
2024+65.8%+25.9%+12.6%+9.1%+3.8%
2025+70.3%+24.7%+12.4%+9.0%+3.7%
PeriodCashDebtNet debtCurrent ratio
2020$1.8B$38.3B$36.5B1.35
2021$1.9B$37B$35.1B1.40
2022$416M$34.9B$34.4B1.22
2023$2.9B$70.8B$68B0.91
2024$1B$67B$66B1.17
2025$1.1B$67.4B$66.3B1.16
PeriodMarket capEnterprise valueP/SP/E
2020$204.5B$241B4.922.3
2021$330.7B$365.8B4.114.9
2022$287.4B$321.8B2.99.2
2023$162.5B$230.5B2.776.7
2024$150.3B$216.2B2.418.7
2025$141.5B$207.8B2.318.3
Q3 2024$17.7B
Q4 2024$17.8B
Q1 2025$13.7B
Q2 2025$14.7B
Q3 2025$16.7B
Q4 2025$17.6B
Q1 2026$14.5B
Q2 2026$15B
PeriodRevenueGrowthNet incomeFCF
Q3 2024$17.7B+31%$4.5B$6.1B
Q4 2024$17.8B+22%$403M$5.8B
Q1 2025$13.7B-8%$3B$1.8B
Q2 2025$14.7B+10%$2.9B-$1.2B
Q3 2025$16.7B-6%$3.5B$4B
Q4 2025$17.6B-1%-$1.6B$4.5B
Q1 2026$14.5B+5%$2.7B$2.2B
Q2 2026$15B+3%-$246M$302M
PeriodGross marginOperating marginNet marginROEROA
Q3 2024+60.8%+28.1%+25.3%+4.8%+2.0%
Q4 2024+73.0%+32.2%+2.3%+0.5%+0.2%
Q1 2025+71.7%+33.7%+21.6%+3.3%+1.4%
Q2 2025+64.3%+24.4%+19.9%+3.3%+1.4%
Q3 2025+74.9%+21.3%+21.3%+3.8%+1.7%
Q4 2025+70.0%+21.0%-9.4%-1.9%-0.8%
Q1 2026+67.3%+27.9%+18.6%+3.0%+1.3%
Q2 2026+72.8%+31.3%-1.6%-0.3%-0.1%
PeriodCashDebtNet debtCurrent ratio
Q3 2024$1.1B$66.6B$65.5B1.00
Q4 2024$1B$63.6B$62.6B1.17
Q1 2025$1.4B$61.3B$59.9B1.26
Q2 2025$1.6B$61.8B$60.2B1.16
Q3 2025$1.3B$61.7B$60.4B1.28
Q4 2025$1.1B$67.4B$66.3B1.16
Q1 2026$1.7B$64.5B$62.8B1.25
Q2 2026$976M$63.2B$62.2B1.27
PeriodMarket capEnterprise valueP/SP/E
Q3 2024$164B$229.5B9.39.2
Q4 2024$150.3B$213B8.591.6
Q1 2025$143.8B$203.7B10.512.1
Q2 2025$137.8B$198B9.411.9
Q3 2025$135.6B$196B8.19.6
Q4 2025$141.5B$207.8B8.1-21.5
Q1 2026$158B$220.8B10.914.8
Q2 2026$138.9B$201.1B9.2-141.0

Refreshed 2h ago

Charts: revenue, profit, cash flow & valuation
Revenue$15BQ2 2026
$4.4B$8.9B$13.3B$17.8BQ3 2023: $13.5BQ4 2023: $14.6BQ1 2024: $14.9BQ2 2024: $13.3BQ3 2024: $17.7BQ4 2024: $17.8BQ1 2025: $13.7BQ2 2025: $14.7BQ3 2025: $16.7BQ4 2025: $17.6BQ1 2026: $14.5BQ2 2026: $15BQ3 2023Q2 2026
Net income-$246MQ2 2026
-$1.4B$565M$2.5B$4.5BQ3 2023: -$2.4BQ4 2023: -$3.3BQ1 2024: $3.1BQ2 2024: $24MQ3 2024: $4.5BQ4 2024: $403MQ1 2025: $3BQ2 2025: $2.9BQ3 2025: $3.5BQ4 2025: -$1.6BQ1 2026: $2.7BQ2 2026: -$246MQ3 2023Q2 2026
EBITDA$1.2BQ2 2026
$485.8M$2.7B$5B$7.3BQ3 2023: -$1.1BQ4 2023: -$1.8BQ1 2024: $5.9BQ2 2024: $2.4BQ3 2024: $7.3BQ4 2024: $5.1BQ1 2025: $5.1BQ2 2025: $5.3BQ3 2025: $5.6BQ4 2025: $756MQ1 2026: $5BQ2 2026: $1.2BQ3 2023Q2 2026
Free cash flow$302MQ2 2026
-$297.8M$1.8B$3.9B$6.1BQ3 2023: $2.6BQ4 2023: $4.2BQ1 2024: $386MQ2 2024: -$2.4BQ3 2024: $6.1BQ4 2024: $5.8BQ1 2025: $1.8BQ2 2025: -$1.2BQ3 2025: $4BQ4 2025: $4.5BQ1 2026: $2.2BQ2 2026: $302MQ3 2023Q2 2026
EPS-$0.04Q2 2026
-$0.25$0.09$0.44$0.78Q3 2023: -$0.42Q4 2023: -$0.6Q1 2024: $0.55Q2 2024: $0Q3 2024: $0.78Q4 2024: $0.07Q1 2025: $0.52Q2 2025: $0.51Q3 2025: $0.62Q4 2025: -$0.29Q1 2026: $0.47Q2 2026: -$0.04Q3 2023Q2 2026
Cash / Debt$976MQ2 2026
$17.7B$35.4B$53.1B$70.8BQ3 2023 · Cash: $3.1BQ3 2023 · Debt: $63.6BQ4 2023 · Cash: $2.9BQ4 2023 · Debt: $70.8BQ1 2024 · Cash: $719MQ1 2024 · Debt: $68.7BQ2 2024 · Cash: $1.1BQ2 2024 · Debt: $68.7BQ3 2024 · Cash: $1.1BQ3 2024 · Debt: $66.6BQ4 2024 · Cash: $1BQ4 2024 · Debt: $63.6BQ1 2025 · Cash: $1.4BQ1 2025 · Debt: $61.3BQ2 2025 · Cash: $1.6BQ2 2025 · Debt: $61.8BQ3 2025 · Cash: $1.3BQ3 2025 · Debt: $61.7BQ4 2025 · Cash: $1.1BQ4 2025 · Debt: $67.4BQ1 2026 · Cash: $1.7BQ1 2026 · Debt: $64.5BQ2 2026 · Cash: $976MQ2 2026 · Debt: $63.2BQ3 2023Q2 2026
CashDebt
Profitability+72.8%Q2 2026
+1.5%+26.0%+50.5%+74.9%Q3 2023 · Gross margin: +21.4%Q4 2023 · Gross margin: +41.0%Q1 2024 · Gross margin: +70.6%Q2 2024 · Gross margin: +62.1%Q3 2024 · Gross margin: +60.8%Q4 2024 · Gross margin: +73.0%Q1 2025 · Gross margin: +71.7%Q2 2025 · Gross margin: +64.3%Q3 2025 · Gross margin: +74.9%Q4 2025 · Gross margin: +70.0%Q1 2026 · Gross margin: +67.3%Q2 2026 · Gross margin: +72.8%Q3 2023 · Operating margin: -22.3%Q4 2023 · Operating margin: -8.7%Q1 2024 · Operating margin: +30.6%Q2 2024 · Operating margin: +14.1%Q3 2024 · Operating margin: +28.1%Q4 2024 · Operating margin: +32.2%Q1 2025 · Operating margin: +33.7%Q2 2025 · Operating margin: +24.4%Q3 2025 · Operating margin: +21.3%Q4 2025 · Operating margin: +21.0%Q1 2026 · Operating margin: +27.9%Q2 2026 · Operating margin: +31.3%Q3 2023 · Net margin: -17.7%Q4 2023 · Net margin: -22.9%Q1 2024 · Net margin: +21.0%Q2 2024 · Net margin: +0.2%Q3 2024 · Net margin: +25.3%Q4 2024 · Net margin: +2.3%Q1 2025 · Net margin: +21.6%Q2 2025 · Net margin: +19.9%Q3 2025 · Net margin: +21.3%Q4 2025 · Net margin: -9.4%Q1 2026 · Net margin: +18.6%Q2 2026 · Net margin: -1.6%Q3 2023Q2 2026
Gross marginOperating marginNet margin
Revenue growth+2.6%Q2 2026
+1.9%+11.7%+21.5%+31.2%Q2 2024: +2.1%Q3 2024: +31.2%Q4 2024: +21.9%Q1 2025: -7.8%Q2 2025: +10.3%Q3 2025: -5.9%Q4 2025: -1.2%Q1 2026: +5.4%Q2 2026: +2.6%Q3 2023Q2 2026
Shares outstanding5.7BQ2 2026
1.4B2.9B4.3B5.7BQ3 2023: 5.6BQ4 2023: 5.6BQ1 2024: 5.7BQ2 2024: 5.7BQ3 2024: 5.7BQ4 2024: 5.7BQ1 2025: 5.7BQ2 2025: 5.7BQ3 2025: 5.7BQ4 2025: 5.7BQ1 2026: 5.7BQ2 2026: 5.7BQ3 2023Q2 2026
Valuation-141.0Q2 2026
314.2769.41,224.61,679.8Q3 2023 · P/E: -20.0Q4 2023 · P/E: -12.1Q1 2024 · P/E: 12.6Q2 2024 · P/E: 1,679.8Q3 2024 · P/E: 9.2Q4 2024 · P/E: 91.6Q1 2025 · P/E: 12.1Q2 2025 · P/E: 11.9Q3 2025 · P/E: 9.6Q4 2025 · P/E: -21.5Q1 2026 · P/E: 14.8Q2 2026 · P/E: -141.0Q3 2023 · P/S: 14.2Q4 2023 · P/S: 11.2Q1 2024 · P/S: 10.5Q2 2024 · P/S: 12.0Q3 2024 · P/S: 9.3Q4 2024 · P/S: 8.5Q1 2025 · P/S: 10.5Q2 2025 · P/S: 9.4Q3 2025 · P/S: 8.1Q4 2025 · P/S: 8.1Q1 2026 · P/S: 10.9Q2 2026 · P/S: 9.2Q3 2023Q2 2026
P/EP/S
Revenue$62.6B2025
$25.1B$50.2B$75.2B$100.3B2018: $53.6B2019: $41.2B2020: $41.7B2021: $81.3B2022: $100.3B2023: $59.6B2024: $63.6B2025: $62.6B20182025
Net income$7.8B2025
$7.8B$15.7B$23.5B$31.4B2018: $11.2B2019: $16.3B2020: $9.2B2021: $22.1B2022: $31.4B2023: $2.1B2024: $8B2025: $7.8B20182025
EBITDA$15.1B2025
$10.3B$20.5B$30.8B$41B2018: $19.6B2019: $18.9B2020: $13.2B2021: $30.8B2022: $41B2023: $9.6B2024: $18.1B2025: $15.1B20182025
Free cash flow$9.1B2025
$7.5B$14.9B$22.4B$29.9B2018: $13.6B2019: $10B2020: $11.6B2021: $29.9B2022: $26B2023: $4.8B2024: $9.8B2025: $9.1B20182025
EPS$1.362025
$1.37$2.74$4.1$5.472018: $1.872019: $2.872020: $1.632021: $3.882022: $5.472023: $0.372024: $1.412025: $1.3620182025
Cash / Debt$1.1B2025
$17.7B$35.4B$53.1B$70.8B2018 · Cash: $1.1B2018 · Debt: $41.7B2019 · Cash: $1.1B2019 · Debt: $50.8B2020 · Cash: $1.8B2020 · Debt: $38.3B2021 · Cash: $1.9B2021 · Debt: $37B2022 · Cash: $416M2022 · Debt: $34.9B2023 · Cash: $2.9B2023 · Debt: $70.8B2024 · Cash: $1B2024 · Debt: $67B2025 · Cash: $1.1B2025 · Debt: $67.4B20182025
CashDebt
Profitability+70.3%2025
+17.9%+35.9%+53.8%+71.7%2018 · Gross margin: +70.2%2019 · Gross margin: +69.3%2020 · Gross margin: +71.7%2021 · Gross margin: +57.7%2022 · Gross margin: +61.9%2023 · Gross margin: +50.9%2024 · Gross margin: +65.8%2025 · Gross margin: +70.3%2018 · Operating margin: +28.5%2019 · Operating margin: +18.2%2020 · Operating margin: +21.8%2021 · Operating margin: +25.6%2022 · Operating margin: +37.4%2023 · Operating margin: +8.9%2024 · Operating margin: +25.9%2025 · Operating margin: +24.7%2018 · Net margin: +20.8%2019 · Net margin: +39.5%2020 · Net margin: +22.0%2021 · Net margin: +27.2%2022 · Net margin: +31.3%2023 · Net margin: +3.6%2024 · Net margin: +12.6%2025 · Net margin: +12.4%20182025
Gross marginOperating marginNet margin
Revenue growth-1.6%2025
-6.7%+27.3%+61.2%+95.2%2019: -23.3%2020: +1.2%2021: +95.2%2022: +23.4%2023: -40.6%2024: +6.8%2025: -1.6%20182025
Shares outstanding5.7B2025
1.5B3B4.5B6B2018: 6B2019: 5.7B2020: 5.6B2021: 5.7B2022: 5.7B2023: 5.7B2024: 5.7B2025: 5.7B20182025
Valuation18.32025
19.238.357.576.72018 · P/E: 21.82019 · P/E: 12.72020 · P/E: 22.32021 · P/E: 14.92022 · P/E: 9.22023 · P/E: 76.72024 · P/E: 18.72025 · P/E: 18.32018 · P/S: 4.52019 · P/S: 5.02020 · P/S: 4.92021 · P/S: 4.12022 · P/S: 2.92023 · P/S: 2.72024 · P/S: 2.42025 · P/S: 2.320182025
P/EP/S

Next catalyst

Catalysts

Earnings
2026-11-03
Revenue est. $15.9B · Updated 2h ago
Dividend
$0.43
2026-07-24

No unusual perp activity right now.

Research data

Analysts, filings and peer context

Estimates

6
DateEPS estimateRevenue estimateGrowthAnalysts
FY 20262.97$62.2B-1%14
FY 20272.90$59.8B-5%14
FY 20282.49$54.8B-12%8
FY 20292.36$52.9B-16%5
FY 20302.44$53.2B-15%5
Q3 20260.76$15.9B-4%11

Company events

6
2026-11-03EarningsActual - / Estimate 0.76-
2026-08-04EarningsActual 0.77 / Estimate 0.68Beat
2026-07-24Dividend$0.43-
2026-05-08Dividend$0.43-
2026-05-05EarningsActual 0.75 / Estimate 0.72Beat
2026-02-03EarningsActual 0.66 / Estimate 0.57Beat

Peer comparison

Similar listed perps

FMP company data

Company intelligence

Updated: Oct 4, 2026, 05:36 PM UTC

Company profile

Sector
Healthcare
Industry
Drug Manufacturers - General
Chief executive
Albert Bourla
Employees
75,000
IPO date
Jun 1, 1972
Country
US
Exchange
New York Stock Exchange
Website
Altman Z-scorei2.08
Piotroski scorei7/9
FMP ratingiB+
Owner earningsi$400.79M$0.07 per share
ESG risk ratingiB+Industry rank: 11 out of 28

Rating factors

Return on equityi
3
Return on assetsi
5
Debt to equityi
1
Price to earningsi
2
Price to booki
4
Market cap history
$158.43B+17.4%Jul 26 – Oct 26
$134.99B$149.33B$163.68BHigh: $163.68B · 2026-09-28Low: $134.99B · 2026-07-06Latest: $158.43B · 2026-10-02Jul 26Aug 26Sep 26Oct 26
Latest: $158.43B · 2026-10-02High: $163.68B · 2026-09-28Low: $134.99B · 2026-07-06
Largest fund holders
FundWeightShares held
VTS.AX0.22%181.1M
VTI0.22%181.1M
VOO0.25%151.4M
IVV0.25%76M
XAW.TO0.15%76M
1557.T0.24%70.3M
SPY0.24%69.9M
FXAIX0.22%64.2M
VTV0.59%54.5M
S5SD.L0.4%46M
XLV2.65%40.4M
VIIIX0.24%30.5M

Analyst track record

How the analysts covering PFE have done: ratings, price-target accuracy and the measured reaction after their calls.

12 months3 years
Ratings185565
Analysts2737
Buy / hold / sell58 / 118 / 9177 / 377 / 11
Upgrades / downgrades / initiations4 / 2 / 47 / 6 / 9
Price targets hit / missed84 / 84 (50%)176 / 324 (35%)
Avg. return after a rating (TipRanks)-1.9%-6.9%
Best / worst call+17.2% / -21.9%+22.3% / -75.6%

After buy calls on this stock: median 21-day move -0.3% vs S&P 500 -2.4% (n = 180)

Most accurate on this stock

Share of an analyst's price targets on this stock that the price reached within 12 months (our measurement over the last 3 years, at least 8 targets). It describes past calls, not the odds of the current one.

  1. Akash TewariJefferies0% hit rate on this stock · 28 targets measuredBuytarget $35.00Oct 2, 2026
  2. Evan SeigermanBMO Capital0% hit rate on this stock · 23 targets measuredBuytarget $30.00Aug 17, 2026
  3. Louise ChenScotiabank0% hit rate on this stock · 15 targets measuredBuytarget $30.00Oct 2, 2026

Latest ratings

DateAnalystCallTarget
Oct 2, 2026Unknown AnalystLeerink PartnersHoldMaintained–
Oct 2, 2026Louise ChenScotiabankBuyMaintained$30.00
Oct 2, 2026Akash TewariJefferiesBuyReiterated$35.00
Oct 2, 2026Michael YeeUBSHoldMaintained$27.00
Oct 2, 2026Akash TewariJefferiesBuyMaintained$35.00
Consensus over the last 12 months buy hold sell avg. target month-end close
Monthly buy, hold and sell shares of analyst ratings with the average price target and the month-end close$24.00$25.00$26.00$27.00$28.00$29.00Nov 25 · Buy 5 · Hold 13 · Sell 1Nov 25Dec 25 · Buy 6 · Hold 14 · Sell 1Jan 26 · Buy 6 · Hold 15 · Sell 1Jan 26Feb 26 · Buy 8 · Hold 14 · Sell 3Mar 26 · Buy 8 · Hold 14 · Sell 2Mar 26Apr 26 · Buy 8 · Hold 14 · Sell 2May 26 · Buy 9 · Hold 14 · Sell 3May 26Jun 26 · Buy 9 · Hold 14 · Sell 2Jul 26 · Buy 8 · Hold 15 · Sell 2Jul 26Aug 26 · Buy 8 · Hold 14 · Sell 2Sep 26 · Buy 8 · Hold 14 · Sell 2Sep 26Oct 26 · Buy 8 · Hold 15 · Sell 2Nov 25 · avg. target $28.64Dec 25 · avg. target $28.37Jan 26 · avg. target $28.25Feb 26 · avg. target $28.64Mar 26 · avg. target $28.98Apr 26 · avg. target $29.02May 26 · avg. target $29.11Jun 26 · avg. target $29.26Jul 26 · avg. target $28.75Aug 26 · avg. target $28.32Sep 26 · avg. target $28.43Oct 26 · avg. target $28.49Nov 25 · month-end close $25.74Dec 25 · month-end close $24.90Jan 26 · month-end close $26.44Feb 26 · month-end close $27.65Mar 26 · month-end close $28.08Apr 26 · month-end close $26.70May 26 · month-end close $26.18Jun 26 · month-end close $24.08Jul 26 · month-end close $25.01Aug 26 · month-end close $28.46Sep 26 · month-end close $28.52Oct 26 · month-end close $27.80

Share of analysts per call each month (latest call per analyst within 180 days). Targets and closes in USD.

TipRanks data via FMP · computed Oct 3, 2026 · 185 ratings

Frequently asked questions

Where can I trade PFE perpetual futures?

Pfizer Inc. (PFE) perpetual futures trade on 4 crypto venues, including Ourbit, MEXC, Helix (Injective). PerpEquities compares them by live price, funding rate, open interest and liquidity.

Can I trade PFE around the clock?

Yes. Unlike the underlying stock, PFE perpetuals trade 24/7 — including weekends and outside regular market hours.

What is the funding rate on PFE perpetuals?

Right now the PFE perp funding rate is -7.2% annualized (venue median), ranging from -14.5% to +24.1% across 4 venues. A positive rate means longs pay shorts. PerpEquities shows the live rate and its history for every venue.

How does the PFE perp price compare to the Pfizer Inc. stock?

The venue-median PFE perp mark is $27.8 versus a reference stock price of $27.8, a basis of 0.0%. Perps follow the stock through an index price; the gap widens when funding or liquidity diverge between venues.

What is a PFE perpetual future?

A PFE perpetual is a derivative that tracks the price of Pfizer Inc. with no expiry date. It lets you take long or short exposure to Pfizer Inc. on crypto venues, around the clock.

What is PFEUSDT perpetual?

PFEUSDT is the symbol most crypto exchanges use for the Pfizer Inc. perpetual settled in USDT (Tether). It tracks the PFE share price through an index, trades 24/7 with leverage and never expires.

Embed this asset

PFE perpetuals · perpequities.comPFE perpetuals · perpequities.com
<a href="https://perpequities.com/stocks/pfe-perp"><img src="https://perpequities.com/badge/pfe-perp.svg" width="240" height="64" alt="PFE perpetuals · perpequities.com" loading="lazy"></a>

Next step

Stay on top of PFE perps

Signals with a track record

Analysts who hit 70%+ of their targets on the perps we track, congress buys over $500k, 13F positions over $5M, funding spreads that have paid for days. Every post shows the evidence. Free, no sign-up.

Join on Telegram

Weekly digest by email

The listings, funding and moves that matter for PFE — one email every Sunday.

Watchlist and alerts

Price and funding alerts for PFE, via push or Telegram.

Set an alert

Follow the live feed

Daily movers, new listings and funding extremes as they happen.

Follow on X